[Cutaneous and soft skin infections due to non-tuberculous mycobacteria]. / Infecciones cutáneas y de partes blandas por micobacterias no tuberculosas.

The frequency of isolation as well as the number of species of non-tuberculous mycobacteria (NTM) has increased in the last years. Nearly every pathogenic species of NTM may cause skin and soft tissue infections, but rapidly growing mycobacteria (Mycobacterium fortuitum, Mycobacterium chelonae and Mycobacterium abscessus), Mycobacterium marinum and Mycobacterium ulcerans are the most commonly involved. Many of these cutaneous mycobacteriosis, such as rapidly growing mycobacteria, M. marinum, Mycobacterium avium complex, Mycobacterium kansasii or Mycobacterium xenopi are world-wide distributed. In contrast, some others have a specific geographical distribution. This is the case of M. ulcerans, which causes a cutaneous diseases endemic of Central and West Africa (Buruli ulcer) and Australia (Bairnsdale ulcer), being the third mycobacterial infection after tuberculosis and leprosy. Cutaneous mycobacteriosis usually appear either after contact of traumatic or surgical wounds with water or other contaminated products, or, secondarily, as a consequence of a disseminated mycobacterial disease, especially among immunosuppressed patients. For an early diagnosis, it is necessary to maintain a high degree of suspicion in patients with chronic cutaneous diseases and a history of trauma, risk exposure and negative results of conventional microbiological studies. In general, individualized susceptibility testing is not recommended for most NTM infections, except for some species, and in case of therapeutic failure. Treatment includes a combination of different antimicrobial agents, but it must be taken into account that NTM are resistant to conventional antituberculous drugs. Severe cases or those with deep tissues involvement could also be tributary of surgical resection.

Noble goals, unforeseen consequences: control of tropical diseases in colonial Central Africa and the iatrogenic transmission of blood-borne viruses.

BACKGROUND: In southern Cameroon, 40-50% of individuals born before 1945 have antibodies against hepatitis C virus (HCV), suggesting massive iatrogenic transmission of at least one blood-borne virus in the region of the world where SIV(cpz) emerged into HIV-1. OBJECTIVE: To estimate the potential role of disease control programs that used intravenous (IV) drugs in the transmission of blood-borne viruses, especially HCV. Methods We reviewed, for 1921-1959, records of health services in Cameroun, Oubangui-Chari, Gabon and Moyen-Congo. We calculated the incidence of diseases whose treatment required the administration of IV drugs, and compared these with previously published data on HCV prevalence. RESULTS: Several IV drugs were used against African trypanosomiasis, leprosy, yaws and syphilis. However, yaws was the only disease whose incidence was high enough so that up to half of some birth cohorts could have acquired HCV. Yaws incidence varied dramatically between regions, and was often >200 per 1000 per year in southern Cameroon, where extremely high HCV prevalence was found. Yaws incidence peaked between 1935 and 1955, a period which coincided with the emergence of HCV and HIV. CONCLUSION: Age, geographical and temporal distributions of yaws suggest that the HCV epidemic in Cameroon was driven by campaigns against yaws (and, secondarily, syphilis) using arsenicals and other metallic drugs. The same interventions may have exponentially amplified other blood-borne viruses, including SIV(cpz)/HIV-1.

[Intensification of the fight against leprosy using early and systematic polychemotherapy]. / Renforcement de la lutte contre la lèpre par une polychimiothérapie précoce et systématique.

The latest epidemiologic enquiries realized in West Africa and Central Africa have shown that real prevalence of leprosy is far greater, at least twice the number of patients than are actually listed in the medical records. This data proves that the fight against leprosy is highly inefficient and stresses the partial failure of the anti-hansenian strategy that has been adopted for over 10 years in this area, in spite of the use of rifampicin in multidrug therapy which would normally cure leprosy. Therefore we suggest that the fight against leprosy should be re-organised and reinforced in high endemic areas. The anti-hansenian programmes should be carried out by specific services composed of mobile and specialised teams whose task would be to aim for the early detection and continual testing for new cases. Only with this kind of organisation can chemotherapy be administered at the beginning, therefore arresting the disease before it reaches the multi-neuritis stage. This strategy offers great epidemiologic and economic advantages and would also give hope and dignity to the patients assured of a permanent cure. Leprosy would then be classed as a disease "just like any other".